Keith Hazleton

Assistant Professor of Clinical Pediatrics

Image of Keith Hazleton
Is this your profile? Click to edit

Overview

Keith Hazleton, MD, PhD is a pediatric hepatologist in the Division of Gastroenterology, Hepatology and Nutrition at Children’s Hospital Los Angeles and Assistant Professor of Clinical Pediatrics at the Keck School of Medicine of USC. His research interests include gut microbiome dysbiosis in pediatric disease, with a focus on diet-microbiome interactions in Clostridioides difficile infection and emerging work on the gut-liver axis in biliary atresia. His PhD training at Albert Einstein College of Medicine focused on purine salvage pathway enzymology and transition state analogue inhibitor development targeting Plasmodium falciparum.

Dr. Hazleton is dedicated to mentoring medical students, residents, and fellows in pediatric gastroenterology and hepatology. He serves on the NASPGHAN Research Committee, where he previously co-chaired the Grants Subcommittee and currently serves on the Abstracts Subcommittee.

Awards

  • American Gastroenterological Association Institute: Gut Microbiota for Health World Summit Travel Award, 2019
  • Front Range Microbiome Symposium: Best Contributed Presentation, 2019

Education and Training

  • Oregon State University , Corvallis, OR — BS — 04/2002 — Biochemistry/Biophysics
  • The Albert Einstein College of Medicine, Bronx, NY — MD — 05/2013 — Medicine
  • The Albert Einstein College of Medicine, Bronx, NY — PhD — 05/2013 — Biomedical Science
  • Children's Hospital Colorado/University of Colorado , Aurora, CO — 06/2015 — General Pediatrics
  • Children's Hospital Colorado/University of Colorado , Aurora, CO — 06/2019 — Pediatric Gastroenterology
  • Children's Hospital Colorado/University of Colorado , Aurora, CO — 06/2020 — Pediatric Advanced/Transplant Hepatology

Research Funding

  • Dietary and synbiotic strategy to limit gut microbiome dysbiosis and protect against Clostridioides difficile infection
    NIH · U01AI150589 · Apr 23, 2021 – Mar 31, 2026 · Role: Co-Investigator

Publications

  • Dietary fiber reduces mortality from secondary sepsis in a murine model of Clostridioides difficile infection. iScience. 2026 Apr 17; 29(4):115258.. View in PubMed
  • The Impact of Diet on Clostridioides difficile Infection: A Review. J Infect Dis. 2025 Jul 11; 231(6):e1010-e1018.. View in PubMed
  • A Multimodal Intervention to Reduce C. difficile Infections and Stool Testing. Pediatrics. 2024 Mar 01; 153(3).. View in PubMed
  • Dietary fat promotes antibiotic-induced Clostridioides difficile mortality in mice. NPJ Biofilms Microbiomes. 2022 04 01; 8(1):15.. View in PubMed
  • Gastric injury secondary to button battery ingestions: a retrospective multicenter review. Gastrointest Endosc. 2020 Aug; 92(2):276-283.. View in PubMed
  • Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother. 2019 12 20; 64(1).. View in PubMed
  • Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018 08; 44:34-40.. View in PubMed
  • Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases. J Biol Chem. 2013 Nov 29; 288(48):34746-54.. View in PubMed
  • Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Bioorg Med Chem. 2013 Sep 01; 21(17):5629-46.. View in PubMed
  • Acyclic immucillin phosphonates: second-generation inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Chem Biol. 2012 Jun 22; 19(6):721-30.. View in PubMed